Skip to content
Triangle logo TriangleGet started
← metastatic Metastatic Squamous Neck Cancer With Occult Primary

NCT00507767 · STUDY IN CONTEXT

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Draft scope assessment: unclear. Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · NOT_STATED

Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.

Analysis per protocol.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-metastatic-squamous-neck-cancer-with-occult-primary-metastatic-305bfb14
nct id
NCT00507767
trial label
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
applicability
unclear
applicability note
Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
1
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-metastatic-squamous-neck-cancer-with-occult-primary-metastatic-305bfb14
    nct id
    NCT00507767
    outcome key
    om-0000
    source section id
    NCT00507767-om-0000
    source outcome index
    0
    endpoint
    Number of Participants With Progression-free Survival at 12-weeks
    endpoint definition
    Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.
    time origin
    At 12-weeks
    analysis role
    primary
    reporting status
    NOT_STATED
    data cutoff
    Source null
    population note
    Analysis per protocol.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-metastatic-squamous-neck-cancer-with-occult-primary-metastatic-305bfb14
    nct id
    NCT00507767
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Dasatinib
    regimen
    100 mg orally twice daily
    analyzed count
    15
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00507767-om-0000#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-metastatic-squamous-neck-cancer-with-occult-primary-metastatic-305bfb14
    nct id
    NCT00507767
    harm key
    EG000
    source section id
    NCT00507767-ae
    event group key
    EG000
    event group label
    Dasatinib
    serious affected
    4
    serious at risk
    15
    other affected
    15
    other at risk
    15
    frequency threshold
    5
    collection period
    Treatment period three 4-week cycles for total of 12 weeks with follow up every 2 cycles following first cycle. Study data collection period for all participants was 18 months.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice